Summary
Cyclic adenosine 3′,5′monophosphate (cAMP) was assayed in CSF and plasma obtained from patients with multiple sclerosis. Decreased CSF cAMP levels were found in more than half of the patients while plasma cAMP was normal. The decrease is correlated significantly with the disability of the patient and with the progression of the disease. A low CSF cAMP level can be considered as prognostically unfavorable, particularly in the early stage of the disease. There was no correlation between the cAMP levels and the duration of the disease or with bouts and remissions. ACTH therapy did not normalize the decreased values. Obviously the decrease of CSF cAMP is related to the demyelination and not to the intensity of the pathological immunoreactions.
Zusammenfassung
Es wurde das cyclische Adenosin-3′,5′monophosphat im Liquor von Patienten mit multipler Sklerose untersucht. Bei einem Teil der Patienten wurden auch die Vergleichswerte im Blutplasma bestimmt. Es zeigte sich bei mehr als der Hälfte der Patienten eine Verminderung der cAMP-Konzentration im Liquor bei normalem Plasmaspiegel. Diese cAMP-Verminderung erwies sich als signifikant abhängig von dem Schweregrad der Erkrankung bzw. der Erkrankungsprogredienz und ist besonders in frühen Erkrankungsfällen als prognostisch ungünstiges Zeichen anzusehen. Es fand sich kein Zusammenhang mit dem Krankheitsstadium, d.h. Schub bzw. Intervall, und mit der Erkrankungsdauer. Eine ACTH-Behandlung vermochte diese Verminderung der Werte nicht auszugleichen. Es wird die Wertigkeit dieser Befunde diskutiert.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brooks BR, Sode J, Engel WK (1976) Cyclic nucleotide metabolism in neuromuscular disease. In: Amyotrophic lateral sclerosis. UCLA Forum Med. Academic Press, San Francisco London
Butcher RW, Sutherland EW (1962) Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of human urine. J Biol Chem 237:1244–1250
Cramer H, Schultz J (1977) Cyclic 3′,5′-nucleotides: Mechanisms of action. Wiley, London New York Sydney Toronto
Heikkinen ER, Myllylä VV, Vapaatalo H, Hokkanen E (1974) Urinary excretion and cerebrospinal fluid concentration of cyclic adenosine 3′,5′-monophosphate in various neurological diseases. Eur Neurol 11:270–280
Heikkinen ER, Similä S, Myllylä VV, Hokkanen E, Vapaatalo H (1975) Cyclic adenosine-3′,5′-monophosphate concentration and enzyme activities of cerebrospinal fluid in meningitis of children. Z Kinderheilk 120:243–250
Heikkinen ER, Myllylä VV, Hokkanen E, Vapaatalo H (1976) Cerebrospinal fluid concentration of cyclic AMP in cerebrovascular diseases. Eur Neurol 14:129–137
Johnson RA, Sutherland EW (1973) Detergent—dispersed adenylate cyclase from rat brain: effects of fluorides, cations and chelators. J Biol Chem 248:5114–5121
Koschel K (1980) The virus—host relationship in CNS model cells. In: Bauer HJ, Poser S, Ritter G (eds) Progress in multiple sclerosis research. Springer, Berlin Heidelberg New York, pp 73–79
Krishna G, Forn J, Voigt K, Paul M, Gessa GL (1970) Dynamic aspects of neurohormonal control cyclic 3′,5′-AMP synthesis in brain. In: Greengard P, Costa E (eds) Role of cyclic AMP in cell function. Adv Biochem Psychopharmacol, vol 3. Raven, New York, pp 155–172
Lehotay DC, Lo HK, Levey GS (1977) Activation of adenylate cyclase: requirement for phospholipids. In: Cramer H, Schultz J (eds) Cyclic 3′,5′-nucleotides: mechanisms of action. Wiley, London New York Sydney Toronto, pp 1–12
Maida E, Summer K (1979) Serum cortisol levels of multiple sclerosis patients during ACTH treatment. J Neurol 220:143–148
Myllylä VV, Vapaatalo H, Hokkanen E, Heikkinen ER (1974) Cerebrospinal fluid concentration of cyclic adenosine 3′,5′-monophosphate and pneumencephalography. Eur Neurol 12:28–32
Myllylä VV, Heikkinen ER, Vapaatalo H, Hokkanen E (1975) Cyclic AMP concentration and enzyme activities of cerebrospinal fluid in patients with epilepsy or central nervous system damage. Eur Neurol 13:123–130
Myllylä VV (1976) Effect of cerebral injury on cerebrospinal fluid cyclic AMP concentration. Eur Neurol 14:413–425
Palmer GC (1979) Neuropharmacology of cyclic nucleotides. Urban & Schwarzenberg, Baltimore Munich
Parker CE (1977) Cyclic nucleotides and the immune response. In: Cramer H, Schultz J (eds) Cyclic 3′,5′-nucleotides: mechanisms of action. Wiley, London New York Sydney Toronto, pp 161–188
Rall TW, Sutherland EW (1962) Adenyl cyclase II., the anzymatically catalysed formation of adenosine 3′,5′-phosphate and inorganic pyrophosphate from adenosine triphosphate. J Biol Chem 232:1065–1070
Robinson GA, Butcher RW, Sutherland EW (1971) The catecholamines. In: Cyclic AMP. Academic Press, New York, pp 146–231
Rodbell M, Birnbaumer L, Pohl SL (1971) Hormones, receptors and adenylcyclase activity in mammalian cells. In: Rall TW, Rodbell M, Condloffe P (eds) The role of adenylcyclase and cyclic 3′,5′-AMP in biological systems. US. Govt. Printing Office, Washington, pp 50–103
Stohlman SA, Sakaguchi AY, Weiner LP (1980) Defective viral infection: the rescue of virus from antigen-negative cells. In: Bauer HJ, Poser S, Ritter G (eds) Progress in multiple sclerosis research. Springer, Berlin Heidelberg New York, pp 59–62
Sutherland EW, Rall TW, Menon T (1962) Adenyl cyclase. J Biol Chem 237:1220–1227
Welch KMA, Meyer JS, Chee AN (1974) Effects of cerebral infarction in man on cyclic AMP levels in CSF and blood. 2nd Int Conf on Cyclic AMP, Vancouver 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maida, E., Kristoferitsch, W. Cyclic adenosine 3′,5′monophosphate in cerebrospinal fluid of multiple sclerosis patients. J Neurol 225, 145–151 (1981). https://doi.org/10.1007/BF00313327
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00313327